StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Organon — Arcoxia (etoricoxib) Worldwide sales by Quarter

Organon — Arcoxia (etoricoxib) Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Organon — Arcoxia (etoricoxib) Worldwide sales: $69,000,000M in Q2 2026, up 9.5% from a year earlier.

Latest, Q2 2026
69,000,000
Period ended Jun 30, 2026
Change on a year earlier
+9.5%
63,000,000 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
17
Documents cited below

Where the Q2 2026 figure comes from

Source: Organon & Co. SEC Filing (0001628280-26-051230) ↗

Reported in Organon & Co. Form 10-Q / 10-K (CIK 0001821825).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOrganon — Arcoxia (etoricoxib) Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202669,000,000+9.5%Organon & Co. SEC Filing (0001628280-26-051230) ↗
Q1 2026Mar 31, 202659,000,000-4.8%Organon & Co. SEC Filing (0001628280-26-029532) ↗
Q4 2025Dec 31, 202570,000,000+18.6%Organon & Co. SEC Filing (0001628280-26-011125) ↗
Q3 2025Sep 30, 202571,000,000+2.9%Organon & Co. SEC Filing (0001628280-25-050795) ↗
Q2 2025Jun 30, 202563,000,000-7.4%Organon & Co. SEC Filing (0001821825-25-000066) ↗
Q1 2025Mar 31, 202562,000,000-17.3%Organon & Co. SEC Filing (0001821825-25-000023) ↗
Q4 2024Dec 31, 202459,000,000+18.0%Organon & Co. SEC Filing (0001821825-25-000006) ↗
Q3 2024Sep 30, 202469,000,000+7.8%Organon & Co. SEC Filing (0001821825-24-000108) ↗
Q2 2024Jun 30, 202468,000,000-5.6%Organon & Co. SEC Filing (0001821825-25-000066) ↗
Q1 2024Mar 31, 202475,000,000+5.6%Organon & Co. SEC Filing (0001821825-25-000023) ↗
Q4 2023Dec 31, 202350,000,000-10.7%Organon & Co. SEC Filing (0001821825-25-000006) ↗
Q3 2023Sep 30, 202364,000,0000.0%Organon & Co. SEC Filing (0001821825-24-000108) ↗
Q2 2023Jun 30, 202372,000,000+18.0%Organon & Co. SEC Filing (0001821825-24-000083) ↗
Q1 2023Mar 31, 202371,000,000+18.3%Organon & Co. SEC Filing (0001821825-24-000056) ↗
Q4 2022Dec 31, 202256,000,000-6.7%Organon & Co. SEC Filing (0001821825-25-000006) ↗
Q3 2022Sep 30, 202264,000,000-1.5%Organon & Co. SEC Filing (0001821825-23-000013) ↗

Breakdown

What makes up organon — Arcoxia (etoricoxib) Worldwide sales

Cite this data

StockData. (2026). Merck Organon — Arcoxia (etoricoxib) Worldwide sales ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn-arcoxia-ww

See every metric in the Merck KPI table. Data updated Oct 26, 2026.